<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="193456">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00573651</url>
  </required_header>
  <id_info>
    <org_study_id>Gardasil in JIA</org_study_id>
    <nct_id>NCT00573651</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis</brief_title>
  <acronym>CHASE</acronym>
  <official_title>Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see if patients with juvenile idiopathic arthritis
      or seronegative arthritis (and related conditions) mount protective immune responses to the
      human papillomavirus (HPV) vaccine called Gardasil. The researchers also want to monitor for
      any increase in disease activity following receipt of the vaccine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each individual subject's participation is scheduled to last approximately two years.
      Patients will be given Gardasil injections at months 0, 2, and 6. Patients will have
      geometric mean titers (GMT) measured at 7, 12, and 24 months. Questionnaires about health
      and function will also be completed at each visit.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2007</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum GMTs at 7 months</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease flare</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peds QL</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure serum GMT</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure serum GMT</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>Group A pauciarticular JIA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Females age 9-26 with pauciarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for serum titres taken to measure antibody and RNA titers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B polyarticular JIA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Females age 9-26 with polyarticular JIA. All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some Blood Draws for Serum Titers taken to measure antibody and RNA titers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C seronegative arthritis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Females age 9-26 with seronegative arthritis (including ankylosing spondylitis and psoriatic arthritis). All study subjects are receiving the Gardasil vaccine as part of their clinical care. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Draws for Serum Titers</intervention_name>
    <description>All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.</description>
    <arm_group_label>Group A pauciarticular JIA</arm_group_label>
    <arm_group_label>Group B polyarticular JIA</arm_group_label>
    <arm_group_label>Group C seronegative arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients, age 9-26 years, with polyarticular JIA, pauciarticular JIA, and
             sero-negative arthritis.

        Exclusion Criteria:

          -  Pregnancy

          -  Known allergy/sensitivity or any hypersensitivity to yeast or components of study
             drug or their formulation

          -  Systemic onset JIA with active systemic symptoms (systemic onset JIA with
             polyarticular features but no fever or rash may be included).

          -  Prior vaccination against HPV

          -  Known HPV infection

          -  Current or history of cervical cancer or cervical intraepithelial neoplasia (CIN).

        Males are excluded from this study because Gardasil® is currently approved only for
        females.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>26 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nora G Singer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UHospitals Cleveland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nora Singer, M.D.</last_name>
    <phone>216-778-5154</phone>
    <email>nora.singer@uhhospitals.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Robinson, M.D.</last_name>
    <phone>216-844-3645</phone>
    <email>angela.robinson@uhhospitals.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Puplava</last_name>
      <phone>773-702-2879</phone>
      <email>rpuplava@peds.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Linda Wagner-Weiner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirk Krogstad</last_name>
      <phone>216-844-1000</phone>
      <email>kirk.krogstad@uhhospitals.org</email>
    </contact>
    <contact_backup>
      <last_name>Sonya Mihalus, RN</last_name>
      <phone>216-844-1000</phone>
      <email>sonya.mihalus@uhhospitals.org</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Brooks, MD,PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Angela Robinson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nellie Coughlin, PNP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MetroHealth</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianne Morus, RRT</last_name>
      <phone>216-778-3309</phone>
      <email>dmorus@metrohealth.org</email>
    </contact>
    <investigator>
      <last_name>Nora Singer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Mawhorter</last_name>
      <phone>216-445-1099</phone>
      <email>MAWHORC@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Steven Spalding</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 17, 2013</lastchanged_date>
  <firstreceived_date>December 13, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals of Cleveland</investigator_affiliation>
    <investigator_full_name>Nora G. Singer</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>JIA</keyword>
  <keyword>SEA syndrome</keyword>
  <keyword>AS</keyword>
  <keyword>psoriatic arthritis</keyword>
  <keyword>HPV vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
